FirsthandHealth
medRxiv PreprintsInternational17 November 2026

Early potassium response to mineralocorticoid receptor antagonist therapy and cardiovascular outcomes in primary aldosteronism: a landmark cohort study

This is an official announcement record

Firsthand records what medRxiv Preprints announced and links to the original. The wording below is theirs, not ours.

Background Mineralocorticoid receptor antagonists (MRAs) are standard therapy for primary aldosteronism (PA). Serum potassium is measured in nearly every treated patient, but the long-term prognostic value of potassium attained early after initiation is undefined. Methods In the TriNetX Research Network, we identified adults with PA newly initiating spironolactone or eplerenone in 2000-2025, without prior adrenalectomy (n=4,169; 180-day landmark design). Achieved potassium (last value on days 14-180) was categorised as <4.0, 4.0-<4.5, 4.5-<5.0 and [&ge;]5.0 mmol/L, and its change from baseline
Source: medRxiv Preprints
Read the official announcement

Opens www.medrxiv.org

More from medRxiv Preprints

This content is for informational purposes only and is not medical advice. It is not intended to diagnose, treat, cure, or prevent any disease. Consult a healthcare professional before starting any supplement, treatment, or program: especially if you are pregnant, nursing, taking medication, or managing a health condition.